LakeShore Biopharma Co (LakeShore Biopharma Co) Total Current Assets : $128.07 Mil (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. LakeShore Biopharma Co's total current assets for the quarter that ended in Sep. 2023 was $128.07 Mil.

LakeShore Biopharma Co Total Current Assets Historical Data

The historical data trend for LakeShore Biopharma Co's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Total Current Assets Chart

LakeShore Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

Total Current Assets

112.61

120.54

150.34

LakeShore Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Total Current Assets	Get a 7-Day Free Trial			-	120.54	124.16	150.34	128.07

LakeShore Biopharma Co Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

LakeShore Biopharma Co's Total Current Assets for the fiscal year that ended in Mar. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	53.71	+	67.198	+	26.902	+	2.53
	=	150.34

LakeShore Biopharma Co's Total Current Assets for the quarter that ended in Sep. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	35.614	+	58.835	+	29.162	+	4.454
	=	128.07

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

LakeShore Biopharma Co (NAS:LSB) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

LakeShore Biopharma Co's Liquidation Value for the quarter that ended in Sep. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	35.614	-	144.451	+	0.75 * 58.835	+	0.5 * 29.162
=	-50.13

LakeShore Biopharma Co Total Current Assets Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.